Advertisement
BIIB or BMY or JNJ
Which Stock Would AI Choose? Biogen (BIIB) vs. Bristol-Myers Squibb (BMY) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- BIIB shares have gained around 18% in recent weeks amid pipeline progress in neurology and rare diseases, outperforming peers in short-term momentum but lacking dividends.
- BMY offers a high dividend yield near 4.3% with a forward P/E of about 9.5, appealing for income-focused investors despite modest YTD gains of roughly 11%.
- JNJ leads YTD performance with over 17% returns, supported by oncology advancements and diversified revenue, trading at a P/E around 22.
- Healthcare sector stability favors JNJ's scale (market cap $585B) over BIIB ($27B) and BMY ($121B), with relative valuation showing BMY as cheapest on forward metrics.
- Recent sentiment shifts highlight BIIB's volatility from generic pressures versus JNJ's consistent catalysts like FDA approvals.
- All three benefit from biotech innovation, but trade-offs exist in growth versus stability and yield.
Introduction
This stock comparison examines BIIB, BMY, and JNJ, three established players in the healthcare sector with focuses on neurology, oncology/cardiology, and diversified pharmaceuticals/medtech. Investors seeking exposure to resilient biotech and pharma amid market volatility may find value here, as these stocks offer contrasts in growth potential, dividend reliability, and risk profiles. Traders monitoring relative performance will note shifts driven by pipeline updates and sector tailwinds, providing insights into current market positioning without speculative forecasts.
BIIB Overview and Recent Performance
Biogen (BIIB), a leader in neurology therapies for multiple sclerosis, Alzheimer's, and rare diseases, has seen shares rise approximately 18% in recent weeks following strong Q4 earnings beats and pipeline advancements. Trading around $182 with a market cap of $27 billion and P/E of 21, sentiment has improved on Phase 3 trials in rare diseases, new product launches like LEQEMBI for Alzheimer's, and optimistic 2026 EPS guidance above $15 per share. However, generic competition on legacy MS drugs has pressured revenues, contributing to longer-term underperformance, though recent momentum reflects reassessed valuations and diversification into immunology.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY), focused on oncology, immunology, and cardiovascular treatments, trades near $59 with a $121 billion market cap and attractive forward P/E of 9.5, alongside a 4.3% dividend yield. YTD gains hover around 11%, supported by positive Phase 3 data on CELMoD programs and pipeline resilience amid patent cliffs. Recent market activity shows modest weekly dips but strength in emerging drugs like Cobenfy, countering competitive pressures from rivals. Sentiment remains steady on strategic developments and raised analyst targets, balancing sales challenges with long-term growth in high-need areas like multiple myeloma and anticoagulants.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), a diversified giant in pharmaceuticals and MedTech, commands a $585 billion market cap with shares around $243, P/E of 22, and 2.15% yield. YTD returns exceed 17%, fueled by oncology pipeline progress, FDA approval of TECNIS PureSee IOL, and Citi's price target hike to $274. Recent performance reflects robust Q4 results and clinical trial expansions, enhancing stability across Innovative Medicine and MedTech segments despite litigation overhangs. Market positioning benefits from broad revenue streams and consistent execution in a volatile environment.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of 25 top-performing AI trading bots from its library of over 351 bots that trade thousands of tickers across diverse strategies, timeframes, and sectors. These bots, analyzed by AI for suitability in current market volatility, feature annualized returns ranging from 17% to over 200%, win rates of 53-95%, and profit factors up to 25.8. Examples include bots targeting semiconductors (up to +110% annualized, 70% win rate), energy/oil (+130%, 62% win rate), and aerospace (+72%, 80% win rate), with trade durations from 1 day to 2 months. Explore these high-conviction signals for real-time opportunities by visiting the Trending AI Robots page.
Head-to-Head Comparison
BIIB, BMY, and JNJ operate in overlapping healthcare domains but diverge in business models: BIIB's neurology specialization versus BMY's oncology focus and JNJ's diversified pharma-MedTech blend. Growth drivers include BIIB's rare disease pipeline, BMY's CELMoDs, and JNJ's oncology trials, with recent momentum strongest for JNJ. Risk factors encompass BIIB's generics exposure, BMY's patent losses, and JNJ's litigation. Valuation sensitivity favors BMY's low forward P/E and yield, while JNJ commands a premium for stability. Sector exposure tilts biotech-heavy for BIIB and BMY, broader for JNJ, with sentiment buoyed by innovation across all.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ based on superior trend consistency, YTD outperformance, diversified catalysts like oncology and MedTech approvals, and relative stability in healthcare volatility. While BMY offers value via yield and low forward multiples, and BIIB shows short-term momentum, JNJ's scale and positioning suggest higher probability of sustained relative strength.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 1 FA rating(s) are green whileBMY’s FA Score has 2 green FA rating(s), and JNJ’s FA Score reflects 3 green FA rating(s).
- BIIB’s FA Score: 1 green, 4 red.
- BMY’s FA Score: 2 green, 3 red.
- JNJ’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 4 TA indicator(s) are bullish while BMY’s TA Score has 6 bullish TA indicator(s), and JNJ’s TA Score reflects 3 bullish TA indicator(s).
- BIIB’s TA Score: 4 bullish, 5 bearish.
- BMY’s TA Score: 6 bullish, 4 bearish.
- JNJ’s TA Score: 3 bullish, 6 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +2.53% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.64% , and JNJ (@Pharmaceuticals: Major) price fluctuated -1.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
Reported Earning Dates
BIIB is expected to report earnings on Apr 29, 2026.
BMY is expected to report earnings on Apr 30, 2026.
JNJ is expected to report earnings on Jul 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BIIB | BMY | JNJ | |
| Capitalization | 26B | 123B | 564B |
| EBITDA | 2.6B | 15.2B | 41.1B |
| Gain YTD | 0.773 | 14.032 | 13.759 |
| P/E Ratio | 20.18 | 17.39 | 21.23 |
| Revenue | 9.89B | 48.2B | 94.2B |
| Total Cash | 3.82B | N/A | 20.1B |
| Total Debt | 6.58B | 47.1B | 47.9B |
BIIB | BMY | JNJ | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 9 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 41 Fair valued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 81 | 11 | |
SMR RATING 1..100 | 78 | 23 | 27 | |
PRICE GROWTH RATING 1..100 | 47 | 21 | 46 | |
P/E GROWTH RATING 1..100 | 14 | 66 | 41 | |
SEASONALITY SCORE 1..100 | 85 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (26) in the Pharmaceuticals Major industry is in the same range as BMY (41) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BIIB (89) in the Biotechnology industry. This means that JNJ's stock grew similarly to BMY’s and somewhat faster than BIIB’s over the last 12 months.
JNJ's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (81) in the Pharmaceuticals Major industry, and is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that JNJ's stock grew significantly faster than BMY’s and significantly faster than BIIB’s over the last 12 months.
BMY's SMR Rating (23) in the Pharmaceuticals Major industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BIIB (78) in the Biotechnology industry. This means that BMY's stock grew similarly to JNJ’s and somewhat faster than BIIB’s over the last 12 months.
BMY's Price Growth Rating (21) in the Pharmaceuticals Major industry is in the same range as JNJ (46) in the Pharmaceuticals Major industry, and is in the same range as BIIB (47) in the Biotechnology industry. This means that BMY's stock grew similarly to JNJ’s and similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (14) in the Biotechnology industry is in the same range as JNJ (41) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BMY (66) in the Pharmaceuticals Major industry. This means that BIIB's stock grew similarly to JNJ’s and somewhat faster than BMY’s over the last 12 months.
| BIIB | BMY | JNJ | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 42% | N/A |
| Stochastic ODDS (%) | 3 days ago 65% | 3 days ago 48% | 3 days ago 42% |
| Momentum ODDS (%) | 3 days ago 57% | 3 days ago 45% | 3 days ago 52% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 55% | 3 days ago 32% |
| TrendWeek ODDS (%) | 3 days ago 58% | 3 days ago 52% | 3 days ago 40% |
| TrendMonth ODDS (%) | 3 days ago 71% | 3 days ago 54% | 3 days ago 42% |
| Advances ODDS (%) | 5 days ago 57% | 3 days ago 54% | 11 days ago 44% |
| Declines ODDS (%) | 10 days ago 72% | 7 days ago 53% | 3 days ago 41% |
| BollingerBands ODDS (%) | 3 days ago 46% | 3 days ago 48% | 3 days ago 48% |
| Aroon ODDS (%) | 3 days ago 64% | 3 days ago 55% | 3 days ago 38% |
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +2.05% | ||
| PFE - BMY | 63% Loosely correlated | +1.25% | ||
| MRK - BMY | 60% Loosely correlated | +3.13% | ||
| AMGN - BMY | 58% Loosely correlated | +1.69% | ||
| BIIB - BMY | 54% Loosely correlated | +0.76% | ||
| ABBV - BMY | 54% Loosely correlated | -0.29% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.